Sánchez WMA, Salazar C

Language: Spanish
References: 12
Page: 53-59
PDF size: 318.50 Kb.

ABSTRACT

Background: In Venezuela, according to MPPS, there were 46 deaths in 2010 due to falciform disorders; two of them in children. Objective: To evaluate in patients with sickle-cell anemia clinical and laboratory parameters before and after treatment with hydroxyurea.
Patients and method: A non-experimental, cross-sectional and retrospective study was done with the data obtained from the medical records of patients who attended the consultation; a nonrandom sample was analyzed for convenience of nineteen patients who met the criteria for inclusion of having clinical complete information in the file: hematimetric indexes, leukocyte and platelet counts before and after treatment with hydroxyurea, painful crises, hospitalizations for any cause, need for using of erythrocyte concentrate, in addition to determine the degree of hematologic toxicity defined by leukopenia, thrombocytopenia or other adverse reactions related to the drug.
Results: Hemoglobin values reported a statistically significant increase after the start of treatment, also improvement in clinical outcomes, decreased number of transfusions and painful crisis. There was an increase in the number of patients who did not were hospitalized after treatment; the most frequent causes of hospitalization were pain crises and infections. Hematologic toxicity hydroxyurea could not be assessed due to lack of information.
Conclusions: Pediatric patients may benefit extensively with the administration of hydroxyurea, thus reducing complications and morbidity from the disease.

REFERENCES

1. López C, De Julián E, Bravo C, Gómez C, et al. Protocolo de anemia de células falciformes o drepanocitosis. Bol S Vasco-Nav Pediatr 2005;38:20-38.

2. Kathryn G. Trastornos de los glóbulos rojos. En: Carol Mattson Porth. Fisiopatología salud- enfermedad: un enfoque conceptual. 7ª ed. Panamericana, 2009;299-319. 59 Sánchez WMA y col. Tratamiento con hidroxiurea de la anemia drepanocítica

3. DeBaun M, Vichinsky E. Hemoglobinopatías. En: Kliegman Behrman Jenson Stanton. Nelson tratado de pediatría. Vol. II. 18ª ed. Elsevier, 2009;2025-2031.

4. Cano G, Posada A. Anemias hemolíticas. En: Correa V JA, Gómez R JF, Posada S R. Fundamentos de pediatría. Tomo IV. 3ª ed. Medellín: Corporación para Investigaciones Biológicas, 2007;25-40.

5. Feliu A, Eberle E, Sciuccati G, Bonduel M. Efecto de la HU en hemoglobina S. Medicina (Buenos Aires) 2003;63:140-142.

6. Matthew H, Russell E. HU en niños con drepanocitosis: Pediatr Clin N Am 2008;55:483-501.

7. Peña A, Hode S, Carrasco L, Verde de López B, López R. Experiencia clínica con el uso de HU en el paciente con anemia drepanocítica. Honduras Pediátrica 1998;19:84- 88.

8. Ware E. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010;115:5300-5311.

9. Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-1554.

10. Wang WC, Wynn L, Rogers ZR, Scott JP, et al. A two-year pilot trial of hydroxyurea in very young children with sicklecell anemia. J Pediatr 2001;139:790-796.

11. Strouse JJ, Lanzkron S, Beach MC, Haywood C, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008;122:1332-1340.

12. González L, Sánchez M, Insausti C. Tratamiento con HU en niños con drepanocitosis. Resultados preliminares. Rev Hematol Mex 2012;13:165-171.